Zynerba Pharmaceuticals’ experimental cannabis-based gel Zygel was not statistically significant in improving aberrant behavior when compared to a placebo in patients with a neurological disorder called Fragile X syndrome.

Boehringer Ingelheim tied up a schizophrenia drug under development by Autifony Limited, a 2011 spinout of GSK, in a deal that could be worth up to about $740 million.